Direct interaction between Rab5a and Rab4a enhanced epidermal growth factor-stimulated proliferation of gastric cancer cells
Open Access
- 15 October 2021
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 13 (10) , 1492-1505
Abstract
Gastric cancer (GC) is one of the leading causes of cancer-related death world wide. Although targeted therapies such as antibodies against human epidermal growth factor receptor 2 or vascular endothelial growth factor receptor 2 have been widely used in the treatment of metastatic cancer, the overall outcomes are poor. Therefore, elucidation of the mechanism underlying cancer progression is important to improve prognosis. Overexpression of the Rab5a gene has been confirmed to correlate with tumorigenesis of many cancers, but the mechanism underling, especially of GC, is still unclear. To investigate the effects of Rab5a overexpression on the tumorigenesis of GC. First, the expression levels of Rab5a and Rab4a in primary tumorous tissues of GC patients diagnosed between 2015 and 2018 were analyzed. Then we constructed HGC-27 cell lines overexpressing green fluorescent protein-Rab5a or red fluorescent protein-Rab4a and investigated the interaction between Rab5a or Rab4a using Western blotting, co-immunoprecipitation, confocal microscopy, and colocalization analysis. Finally, epidermal growth factor-stimulated proliferation of these cell lines was analyzed using cell counting kit-8 cell viability assay. Compared with normal gastric tissues, the expression levels of Rab5a and Rab4a increased progressively both in paracancerous tissues and in advanced cancerous tissues. Epidermal growth factor could promote the proliferation of HGC-27 cells, especially Rab5a-overexpressing HGC-27 cells. Notably, Rab5a and Rab4a co-overexpression promoted the proliferation of HGC-27 cells to the greatest extent. Further analysis identified a direct interaction between Rab5a and Rab4a in HGC-27 cells. Co-overexpression of Rab5a and Rab4a in GC may promote the endosomal recycling of epidermal growth factor receptor, which in turn contributes to poor prognosis and tumor progression in GC patients. Inhibition of Rab5a or Rab4a expression might be a promising therapy for refractory GC.Keywords
This publication has 41 references indexed in Scilit:
- Reconstruction of an Integrated Genome-Scale Co-Expression Network Reveals Key Modules Involved in Lung AdenocarcinomaPLOS ONE, 2013
- SnapShot: Mammalian Rab Proteins in Endocytic TraffickingCell, 2012
- Rab5A is associated with axillary lymph node metastasis in breast cancer patientsCancer Science, 2011
- Procathepsin L secretion, which triggers tumour progression, is regulated by Rab4a in human melanoma cellsBiochemical Journal, 2011
- Rab5a overexpression promoting ovarian cancer cell proliferation may be associated with APPL1‐related epidermal growth factor signaling pathwayCancer Science, 2010
- Expression of Rab5a in hepatocellular carcinoma: Possible involvement in epidermal growth factor signalingHepatology Research, 2007
- Visualization of Rab5 activity in living cells by FRET microscopy and influence of plasma-membrane-targeted Rab5 on clathrin-dependent endocytosisJournal of Cell Science, 2003
- Divalent Rab effectors regulate the sub-compartmental organization and sorting of early endosomesNature Cell Biology, 2002
- Co‐operative regulation of endocytosis by three RAB5 isoformsFEBS Letters, 1995
- The involvement of the small GTP-binding protein Rab5a in neuronal endocytosisNeuron, 1994